Reservoir Neuroscience, Inc.
Therapeutics designed to heal the blood-brain barrier
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Founded
- 2019
- Latest Form D
- $3M, Jun 2026
- Total capital
- $9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $9M
- 3 Form D · last Jun 2026
- 4 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 8 pending · first 2025
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$3M
- Private capital raisedForm D · SEC · 2nd filing$2.1M
- Private capital raisedForm D · SEC · 1st filing$3.9M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Aaron FriedmanExecutive Officer, DirectorNamed in SEC Form D filings
- Brian SlingerlandDirectorNamed in SEC Form D filings
- James SummersDirectorNamed in SEC Form D filings
- Patrick BurgermeisterDirectorNamed in SEC Form D filings
- Tracy SaxtonDirectorNamed in SEC Form D filings
- Vladimir SenatorovExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 10- GrantedEP2 Antagonist CompoundsUSPTOUS 12,624,024
- PendingEP2 Antagonist CompoundsUSPTOApplication 19056593
- GrantedEP2 Antagonist CompoundsUSPTOUS 12,297,171
Show all 10 patent records
- EP2 Antagonist CompoundsMay 12, 2026 · US 12,624,024Granted
- EP2 Antagonist CompoundsJun 12, 2025 · Application 19056593Pending
- EP2 Antagonist CompoundsMay 13, 2025 · US 12,297,171Granted
- EP2 Antagonist CompoundsApplication PCTUS2022034901Pending
- EP2 Antagonist CompoundsApplication 19477755Pending
- EP2 Antagonist CompoundsApplication 63214635Pending
- EP2 Antagonist CompoundsApplication 63214645Pending
- EP2 Antagonist CompoundsApplication PCTUS2022034903Pending
- EP2 Antagonist CompoundsApplication 63435738Pending
- EP2 Antagonist CompoundsApplication 63435730Pending
Related companies, and why
- Umoja BiopharmaSimilar federal contract value in Biotech · null in contracts
- ADARx PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- COARE HOLDINGS INCSimilar federal contract value in Biotech · null in contracts
- Carmot Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- IGM BiosciencesSimilar federal contract value in Biotech · null in contracts
- REVOPSIS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .